US Edition
Innate Pharma highlights durable responses to lacutamab in Sezary syndrome and mycosis fungoides
Summary by Innate-pharma.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Innate Pharma highlights durable responses to lacutamab in Sezary syndrome and mycosis fungoides
Innate Pharma highlights durable responses to lacutamab in Sezary syndrome and mycosis fungoides Fri, 05/23/2025 - 07:00 Press Release in English 230.44 KB Communiqué de presse en français 188.74 KB mathilde Thu, 05/22/2025
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
